ITCA 650
Revolutionizing type 2 diabetes treatment with Intarcia delivery technology and a 'gold-standard' of care -- exenatide
The DUROS device is a subcutaneous osmotic mini-pump. Each device contains an appropriate volume of drug product to treat a patient for a predetermined extended duration of time.
Although significant advances have been made in the management of type 2 diabetes, current treatment options still fall short of delivering superior outcomes for many patients. With suboptimal glycemic control and continued weight gain, patients face the prospect of disease progression, which is characterized by a continuing decline in beta-cell mass and function and worsening insulin resistance1. Therefore, more effective therapies that promote adherence and control are desperately needed. Without this, the needless but potentially serious consequences of poorly controlled type 2 diabetes are likely to continue to occur among an alarming number of patients.
GLP-1 receptor agonists, like exenatide, have shown great potential as a type 2 diabetes treatment. GLP-1s provide profound glycemic control and a favorable weight profile. However, the use of GLP-1s has been limited as they require patients to inject themselves once or twice daily. These injectable therapies also result in fluctuating drug levels, which may contribute to undesirable side effects including nausea.
Intarcia’s ITCA 650 is an investigational new form of GLP-1 therapy, which holds the promise of addressing these challenges and transforming the diabetes treatment landscape. ITCA 650 is designed so that patients receive a continuous flow of therapy from a matchstick-sized device placed under the skin for up to a year to provide optimal glycemic control, tolerability, and adherence with treatment.
|
The Problem of DiabetesType 2 diabetes is the most common form of diabetes, and is triggered by a combination of risk factors that include older age, obesity, family history, having diabetes while pregnant, a sedentary lifestyle and race/ethnicity.2 Currently, 1 in 10 Americans have type 2 diabetes and 25 percent of them do not even know it. According to a 2010 report from the Centers for Disease Control and Prevention (CDC), 1 in 3 people in the U.S. will have type 2 diabetes by 2050 if current trends continue. As a result of the increasing prevalence of the disease, diabetes alone could account for about one one-tenth of the nation’s healthcare bills--approximately $500 billion annually.3 |
1 Fonseca VA. Defining and characterising progression of type 2 diabetes. Br J Diab Vasc Dis 2008; 8: S3.
2 Mayo Clinic: http://www.mayoclinic.com/health/type-2-diabetes/DS00585/DSECTION=risk-factors
3 Centers for Disease Control: http://www.cdc.gov/media/pressrel/2010/r101022.html
Take a Closer Look: DUROS Technology
Overview
The DUROS® subcutaneous delivery system is comprised of a small, matchstick-sized osmotic pump that is inserted subcutaneously (just beneath the skin) to deliver a slow and consistent flow of medication. Each device contains an appropriate volume of drug product to treat a patient for a predetermined extended duration of time.
